< 1 minute read
Sep. 17, 2021

MRTX849: A Covalent KRASG12C Inhibitor

MRTX849

covalent KRASG12C inhibitor in clinical development for KRASG12C+ cancers from optimization of known starting point J. Med. Chem., Apr. 6, 2020 Array / Mirati Therapeutics

drughunter.com
Drug Hunter Team

April 2020’s molecule, the Mirati KRAS G12C inhibitor MRTX849 , has been a hotly followed compound in development as it is the closest clinical KRAS inhibitor to the likely soon-to-be approved AMG-510 (sotorasib). The KRAS clinical race easily would have been the most followed development story of 2020 had it not been for COVID, due to the [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in